Isoforskolin, adenylate cyclase agonist, inhibits endothelial-to-mesenchymal transition in atherosclerosis

被引：0

作者：

Ma, Yiming ^{[1
]}

Shi, Yunke ^{[1
]}

Lun, Jinping ^{[1
]}

Wang, Mingqiang ^{[1
]}

Zhang, Chaoyue ^{[1
]}

Li, Xianbin ^{[1
]}

Yi, Qian ^{[2
]}

Cao, Xingyu ^{[1
]}

Hu, Zhao ^{[3
]}

Yang, Weimin ^{[2
]}

Cai, Hongyan ^{[1
]}

机构：

[1] Kunming Med Univ, Affiliated Hosp 1, Heart Ctr, Kunming 650032, Yunnan, Peoples R China

[2] Kunming Med Univ, Sch Pharmaceut Sci, Yunnan Key Lab Pharmacol Nat Prod, Kunming 650500, Peoples R China

[3] Kunming Med Univ, Affiliated Hosp 1, Geriatr Cardiol Dept, Kunming 650032, Yunnan, Peoples R China

来源：

PHYTOMEDICINE | 2025年 / 139卷

关键词：

Atherosclerosis; Isoforskolin; Adenylyl cyclase; Endothelial-to-mesenchymal transition; PROTEIN-COUPLED RECEPTORS; HEART-RATE; INFLAMMATION; EXPRESSION; CAMP; MICROGRAVITY; ISOFORMS; CELLS;

D O I：

10.1016/j.phymed.2025.156520

中图分类号：

Q94 [植物学];

学科分类号：

071001 ;

摘要：

Background: Atherosclerosis is a common chronic disease characterized by the formation of atheromatous plaques and endothelial dysfunction. Endothelial-to-mesenchymal transition (EndMT) has been identified as a crucial driver of atherosclerosis, with TGF-(3 serving as a pivotal mediator of EndMT. Isoforskolin (ISOF), derived from the plant Coleus forskohlii, is an effective activator of adenylyl cyclase (AC). AC can catalyze the production of cyclic adenosine monophosphate (cAMP), mediating various biological functions. Several phosphodiesterase (PDE) inhibitors that degrade cAMP have been clinically utilized in the treatment of atherosclerosis. However, the evidence regarding the efficacy and mechanisms of AC agonists in the treatment of atherosclerosis remains inadequate. Purpose: In this study, our primary objective was to examine the therapeutic impact of ISOF on atherosclerosis and elucidate its potential mechanisms. Methods: Male ApoE-/- rats were fed a high-fat diet for 18 weeks and then administered ISOF by gavage continuously for 12 weeks. A cell model was established by injuring mouse aortic endothelial cells (MAECs) with ox-LDL. Oil Red O staining and Masson staining were used to assess the plaque area and content of collagen. Aortic vasodilatory function was analyzed using the DMT Myograph system. Immunofluorescence was used to determine the localization of CD31 and alpha-SMA. Proteomics analysis was utilized to identify potential pharmacological mechanisms of ISOF. Quantitative real-time polymerase chain reaction (qRT-PCR) was conducted to detect the mRNA expression levels of AC (1-10) in aortic tissue. AC activity and cAMP concentration were detected using specific kits. The CCK-8 assay, wound-healing, and transwell assays were used to measure cell viability and proliferation. Mechanistically, western blot analysis was used to detect candidate protein expression levels. Finally, the pharmacological knockdown of AC5 was employed to clarify the potential mechanism of ISOF. Results: ISOF effectively inhibited atherosclerotic plaque progression and improved aortic vasodilatory function in ApoE-/- rats fed a high-fat diet. At the cellular level, ISOF enhanced cell viability and proliferation of MAECs compromised by ox-LDL. These phenotypic improvements were attributed to the inhibitory effect of ISOF on endothelial-to-mesenchymal transition (EndMT); ISOF increased the expression of endothelial markers such as CD31 and E-cadherin while decreasing the expression of mesenchymal markers, including N-cadherin and alpha-SMA. Mechanistically, and consistent with the results of proteomic analysis, ISOF markedly inhibited the TGF(3/Smad3 signaling pathway both in vivo and in vitro. Furthermore, the expression levels of adenylyl cyclase 5 (AC5) were significantly higher than those of other AC isoforms in rat aorta. ISOF might upregulate the expression of AC5, subsequently activating downstream protein kinase A (PKA) but not cAMP-activated exchange protein-1 (EPAC1). However, when AC5 was silenced, the effects of ISOF on EndMT and the cAMP/PKA/ TGF-(3 pathway were effectively abolished. Conclusion: The study showed that ISOF effectively combats atherosclerosis by inhibiting EndMT through the regulation of the AC5-dependent cAMP/PKA/TGF-(3 axis. This finding suggests a potential promising therapeutic strategy for treating atherosclerosis.

引用

页数：14

共 55 条

[1] Bai Y., Tsunematsu T., Jiao Q., Ohnuki Y., Mototani Y., Shiozawa K., Jin M., Cai W., Jin H.L., Fujita T., Ichikawa Y., Suita K., Kurotani R., Yokoyama U., Sato M., Iwatsubo K., Ishikawa Y., Okumura S., Pharmacological stimulation of type 5 adenylyl cyclase stabilizes heart rate under both microgravity and hypergravity induced by parabolic flight, J. Pharmacol. Sci., 119, 4, pp. 381-389, (2012)
[2] Cai Y., Li J.D., Yan C., Vinpocetine attenuates lipid accumulation and atherosclerosis formation, Biochem. Biophys. Res. Commun., 434, 3, pp. 439-443, (2013)
[3] Chen M.L., Yi L., Jin X., Liang X.Y., Zhou Y., Zhang T., Xie Q., Zhou X., Chang H., Fu Y.J., Zhu J.D., Zhang Q.Y., Mi M.T., Resveratrol attenuates vascular endothelial inflammation by inducing autophagy through the cAMP signaling pathway, Autophagy, 9, 12, pp. 2033-2045, (2013)
[4] Chen P.Y., Qin L., Baeyens N., Li G., Afolabi T., Budatha M., Tellides G., Schwartz M.A., Simons M., Endothelial-to-mesenchymal transition drives atherosclerosis progression, J. Clin. Invest., 125, 12, pp. 4514-4528, (2015)
[5] Chen P.Y., Qin L., Li G., Wang Z., Dahlman J.E., Malagon-Lopez J., Gujja S., Cilfone N.A., Kauffman K.J., Sun L., Sun H., Zhang X., Aryal B., Canfran-Duque A., Liu R., Kusters P., Sehgal A., Jiao Y., Anderson D.G., Gulcher J., Fernandez-Hernando C., Lutgens E., Schwartz M.A., Pober J.S., Chittenden T.W., Tellides G., Simons M., Endothelial TGF-β signalling drives vascular inflammation and atherosclerosis, Nat. Metab., 1, 9, pp. 912-926, (2019)
[6] Chen P.Y., Schwartz M.A., Simons M., Endothelial-to-mesenchymal transition, Vascular Inflammation, and Atherosclerosis, Front Cardiovasc. Med., 7, (2020)
[7] Cheng C., Zhang J., Li X., Xue F., Cao L., Meng L., Sui W., Zhang M., Zhao Y., Xi B., Yu X., Xu F., Yang J., Zhang Y., Zhang C., NPRC deletion mitigated atherosclerosis by inhibiting oxidative stress, inflammation and apoptosis in ApoE knockout mice, Signal. Transduct. Target. Ther., 8, 1, (2023)
[8] Colombe A.S., Pidoux G., Cardiac cAMP-PKA signaling compartmentalization in myocardial infarction, Cells, 10, 4, (2021)
[9] Defer N., Best-Belpomme M., Hanoune J., Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase, Am. J. Physiol. Renal. Physiol., 279, 3, pp. F400-F416, (2000)
[10] Dong Y., Wang B., Du M., Zhu B., Cui K., Li K., Yuan K., Cowan D.B., Bhattacharjee S., Wong S., Shi J., Wang D.Z., Chen K., Bischoff J., Linton M.F., Chen H., Targeting epsins to inhibit fibroblast growth factor signaling while potentiating transforming growth factor-β signaling constrains endothelial-to-mesenchymal transition in atherosclerosis, Circulation, 147, 8, pp. 669-685, (2023)

← 1 2 3 4 5 6 →